Sukumar Nagendran sold $1.2M of Taysha Gene Therapies (TSHA)

Executed Jul 10, disclosed Jul 10, the same day.

Value, as filed

$1.2M

200,000 sh × $6.24

Executed

Jul 10

the trade date, as filed

Disclosed

Jul 10

0 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Sukumar Nagendran President and Head of R&D profile →

Sukumar Nagendran (President and Head of R&D) filed 5 Form 4 reports in the trailing twelve months (0 purchases, 5 sales), most often in Taysha Gene Therapies, Inc. (TSHA). The largest single filing was $1.7M of TSHA (370,172 sh across 2 lots, as filed), executed Nov 28 2025.

The name

TSHA

Taysha Gene Therapies, Inc. TSHA · Healthcare · 11 filings in 24 months ticker →

Healthcare · Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Sukumar Nagendran in TSHA

TSHASALE Taysha Gene Therapies, Inc. $892K
200,000 sh × $4.46
Exec Apr 10
Filed Apr 13 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $547K
116,050 sh across 2 lots
Exec Jan 23
Filed Jan 27 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $942K
200,000 sh × $4.71
Exec Jan 12
Filed Jan 14 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $1.7M
370,172 sh across 2 lots
Exec Nov 28 2025
Filed Dec 1 2025 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $646K
200,000 sh × $3.23
Exec Sep 10 2025
Filed Sep 12 2025 · 5:30 PM ET TSHASALE Taysha Gene Therapies, Inc. $163K
57,054 sh × $2.85
Exec Aug 21 2025
Filed Aug 22 2025 · 5:30 PM ET